Hypoxia and MITF regulate KIT oncogenic properties in melanocytes

被引:8
作者
Laugier, F. [1 ,2 ]
Delyon, J. [1 ,2 ]
Andre, J. [1 ,2 ]
Bensussan, A. [1 ,2 ]
Dumaz, N. [1 ,2 ]
机构
[1] Hop St Louis, Ctr Rech Peau, INSERM, U976, Paris, France
[2] Univ Paris Diderot, Sorbonne Paris Cite, UMRS976, Paris, France
关键词
STEM-CELL FACTOR; HUMAN-MELANOMA CELLS; METASTATIC MELANOMA; SIGNAL-TRANSDUCTION; OXYGEN; SKIN; ACTIVATION; EXPRESSION; SURVIVAL; IMATINIB;
D O I
10.1038/onc.2016.39
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
KIT mutations are frequent in acral, mucosal and chronic sun-damage (CSD) melanoma, but little is known about the mechanisms driving the transformation of KIT-mutated melanocytes into melanoma cells. We showed that exposition of melanocytes harboring the L576PKIT mutation to a hypoxic environment induced their transformation into malignant cells. Transformed L576PKIT melanocytes showed downregulation of MITF expression characteristic of melanoma initiating cells (MICs). In agreement, these cells were able to form spheres in neural crest cell medium and low-adherence conditions, also a characteristic of MICs. Downregulation of MITF by RNA interference induced transformation of KIT-mutated melanocytes in normoxia and acquisition of a MIC phenotype by these cells. Hence, low level of MITF cooperates with oncogenic KIT to transform melanocytes. Activation of the cAMP pathway in transformed L576PKIT melanocytes stimulated MITF expression, and reduced cellular proliferation and sphere formation. These findings highlight the essential role of MITF in revealing the oncogenic activity of KIT in melanocytes and suggest that the cAMP pathway is a therapeutic target in KIT-mutated melanoma.
引用
收藏
页码:5070 / 5077
页数:8
相关论文
共 39 条
[1]   Targeting Activated KIT Signaling for Melanoma Therapy [J].
Bastian, Boris C. ;
Esteve-Puig, Rosaura .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3288-+
[2]   The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation [J].
Bedogni, B ;
Welford, SM ;
Cassarino, DS ;
Nickoloff, BJ ;
Giaccia, AJ ;
Powell, MB .
CANCER CELL, 2005, 8 (06) :443-454
[3]   Hypoxia, melanocytes and melanoma - survival and tumor development in the permissive microenvironment of the skin [J].
Bedogni, Barbara ;
Powell, Marianne Broome .
PIGMENT CELL & MELANOMA RESEARCH, 2009, 22 (02) :166-174
[4]   A LINE OF NONTUMORIGENIC MOUSE MELANOCYTES, SYNGENEIC WITH THE B-16 MELANOMA AND REQUIRING A TUMOR PROMOTER FOR GROWTH [J].
BENNETT, DC ;
COOPER, PJ ;
HART, IR .
INTERNATIONAL JOURNAL OF CANCER, 1987, 39 (03) :414-418
[5]   Genetic variation at KIT locus may predispose to melanoma [J].
Bourillon, Agnes ;
Hu, Hui-Han ;
Hetet, Gilles ;
Lacapere, Jean-Jacques ;
Andre, Jocelyne ;
Descamps, Vincent ;
Basset-Seguin, Nicole ;
Ogbah, Zighereda ;
Puig, Susana ;
Saiag, Philippe ;
Bagot, Martine ;
Bensussan, Armand ;
Grandchamp, Bernard ;
Dumaz, Nicolas ;
Soufir, Nadem .
PIGMENT CELL & MELANOMA RESEARCH, 2013, 26 (01) :88-96
[6]   KIT as a Therapeutic Target in Metastatic Melanoma [J].
Carvajal, Richard D. ;
Antonescu, Cristina R. ;
Wolchok, Jedd D. ;
Chapman, Paul B. ;
Roman, Ruth-Ann ;
Teitcher, Jerrold ;
Panageas, Katherine S. ;
Busam, Klaus J. ;
Chmielowski, Bartosz ;
Lutzky, Jose ;
Pavlick, Anna C. ;
Fusco, Anne ;
Cane, Lauren ;
Takebe, Naoko ;
Vemula, Swapna ;
Bouvier, Nancy ;
Bastian, Boris C. ;
Schwartz, Gary K. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22) :2327-2334
[7]   Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells [J].
Cheli, Y. ;
Giuliano, S. ;
Fenouille, N. ;
Allegra, M. ;
Hofman, V. ;
Hofman, P. ;
Bahadoran, P. ;
Lacour, J-P ;
Tartare-Deckert, S. ;
Bertolotto, C. ;
Ballotti, R. .
ONCOGENE, 2012, 31 (19) :2461-2470
[8]   Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny [J].
Cheli, Y. ;
Guiliano, S. ;
Botton, T. ;
Rocchi, S. ;
Hofman, V. ;
Hofman, P. ;
Bahadoran, P. ;
Bertolotto, C. ;
Ballotti, R. .
ONCOGENE, 2011, 30 (20) :2307-2318
[9]   Distinct sets of genetic alterations in melanoma [J].
Curtin, JA ;
Fridlyand, J ;
Kageshita, T ;
Patel, HN ;
Busam, KJ ;
Kutzner, H ;
Cho, KH ;
Aiba, S ;
Bröcker, EB ;
LeBoit, PE ;
Pinkel, D ;
Bastian, BC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2135-2147
[10]   Somatic activation of KIT in distinct subtypes of melanoma [J].
Curtin, John A. ;
Busam, Klaus ;
Pinkel, Daniel ;
Bastian, Boris C. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4340-4346